RhumbLine Advisers’s RxSight RXST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$284K Buy
46,175
+2,305
+5% +$19.1K ﹤0.01% 2930
2025
Q4
$457K Sell
43,870
-7,566
-15% -$75.9K ﹤0.01% 2718
2025
Q3
$462K Sell
51,436
-6,655
-11% -$58.4K ﹤0.01% 2752
2025
Q2
$755K Buy
58,091
+6,515
+13% +$98K ﹤0.01% 2392
2025
Q1
$1.3M Buy
51,576
+3,103
+6% +$92.2K ﹤0.01% 2049
2024
Q4
$1.67M Buy
48,473
+1,663
+4% +$75K ﹤0.01% 1983
2024
Q3
$2.31M Sell
46,810
-655
-1% -$33.6K ﹤0.01% 1824
2024
Q2
$2.86M Buy
47,465
+8,632
+22% +$493K ﹤0.01% 1699
2024
Q1
$2M Buy
38,833
+1,275
+3% +$62.6K ﹤0.01% 1914
2023
Q4
$1.51M Buy
37,558
+1,728
+5% +$50.7K ﹤0.01% 2050
2023
Q3
$999K Buy
35,830
+1,148
+3% +$34.2K ﹤0.01% 2213
2023
Q2
$999K Buy
34,682
+3,967
+13% +$88.2K ﹤0.01% 2289
2023
Q1
$512K Buy
30,715
+4,795
+18% +$67.7K ﹤0.01% 2425
2022
Q4
$328K Buy
25,920
+567
+2% +$6.9K ﹤0.01% 2644
2022
Q3
$304K Buy
25,353
+1,688
+7% +$23.2K ﹤0.01% 2723
2022
Q2
$333K Buy
23,665
+11,312
+92% +$149K ﹤0.01% 2706
2022
Q1
$153K Buy
+12,353
New +$148K ﹤0.01% 2814

Other funds holding RXST

RhumbLine Advisers's RXST Position: Q1 2026 in Review

RhumbLine Advisers increased its RxSight (RXST) stake by 5.3% in Q1 2026, buying an estimated $19.1K and bringing the position to 46,175 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #2930.

RhumbLine Advisers first reported a position in RXST in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.86M in Q2 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

  • RhumbLine Advisers held 46,175 shares of RxSight worth $284K as of Q1 2026.
  • RhumbLine Advisers bought 2,305 RxSight shares in Q1 2026, an estimated $19.1K.
  • RxSight made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2930 holding.
  • RhumbLine Advisers first reported a position in RxSight in Q1 2022 and has held it in 17 quarters since.
  • RhumbLine Advisers's RxSight position peaked at $2.86M in Q2 2024.
  • 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.